Results 281 to 290 of about 114,443 (322)
Some of the next articles are maybe not open access.
Aprotinin: A Pharmacologic Overview
Orthopedics, 2004abstractAprotinin is a polypeptide with serine protease inhibitory activity of key enzymes associated with inflammatory, fibrinolytic, and hemostatic pathways. The drug binds directly to the fibrinolytic plasmin at the lower plasmin-inhibiting dose (plasma concentration, 137 KlU/mL), and the inflammatory mediator, kallikrein, using the higher ...
Edward Sypniewski, Jerrold H. Levy
openaire +3 more sources
Expert Review of Cardiovascular Therapy, 2006
Aprotinin is a naturally occurring serine protease inhibitor that is being used with increasing frequency in cardiac surgery and beyond to reduce blood loss and the need for perioperative blood transfusion. Through inhibition of serine proteases such as plasmin, aprotinin significantly reduces fibrinolysis, thereby aiding hemostasis during surgical ...
Munir Boodhwani +4 more
openaire +3 more sources
Aprotinin is a naturally occurring serine protease inhibitor that is being used with increasing frequency in cardiac surgery and beyond to reduce blood loss and the need for perioperative blood transfusion. Through inhibition of serine proteases such as plasmin, aprotinin significantly reduces fibrinolysis, thereby aiding hemostasis during surgical ...
Munir Boodhwani +4 more
openaire +3 more sources
Aprotinin, a carbohydrate-binding protein [PDF]
Histochemie, 1973 Evidence is presented for a carbohydrate-binding property of aprotinin, which is preserved both in a fluorescein isothiocyanate (FITC) conjugate and a cyanogen bromidelinked Sepharose conjugate of the protein. Both conjugates similarly retain their tryptic and chymotryptic inhibitory properties.
John A. Kiernan, R. W. Stoddart
openaire +2 more sources
The Annals of Thoracic Surgery, 1993
Aprotinin is a nonspecific serine protease inhibitor extracted from bovine lung. It was first used during cardiopulmonary bypass to inhibit plasmin-induced complement activation. By chance significant reductions of blood loss and blood requirements were noted in treated patients.
openaire +3 more sources
Aprotinin is a nonspecific serine protease inhibitor extracted from bovine lung. It was first used during cardiopulmonary bypass to inhibit plasmin-induced complement activation. By chance significant reductions of blood loss and blood requirements were noted in treated patients.
openaire +3 more sources
Aprotinin does not prolong the Sonoclot aprotinin-insensitive activated clotting time [PDF]
Journal of Clinical Anesthesia, 2007 To determine whether a new Sonoclot-based, aprotinin-insensitive activated clotting time (aiACT) assay yields stable results over a broad range of aprotinin concentrations.Prospective trial conducted on in vitro blood samples.Tertiary-care teaching medical center.19 healthy adult volunteers.Whole blood samples were collected from volunteers. Heparin (2
William C. Oliver +4 more
openaire +2 more sources
Aprotinin and Anaphylaxis: Analysis of 12,403 Exposures to Aprotinin in Cardiac Surgery
The Annals of Thoracic Surgery, 2007Hypersensitivity reactions to the nonspecific proteinase inhibitor aprotinin may occur. The present study evaluates the incidence of hypersensitivity reactions to aprotinin.Data were prospectively collected as part of the institution's quality assurance program.
Anna-Laure Boulesteix +3 more
openaire +3 more sources
1991
Monitoring of the adequacy of anticoagulation is essential to the safe conduct of cardiopulmonary bypass (CPB). While there is no universally accepted heparin level or test of adequate anticoagulation during cardio-pulmonary bypass, the automated activated clotting time (Hemochron ACT) became the routine method of monitoring heparinization in most ...
H. Kiefer +3 more
openaire +2 more sources
Monitoring of the adequacy of anticoagulation is essential to the safe conduct of cardiopulmonary bypass (CPB). While there is no universally accepted heparin level or test of adequate anticoagulation during cardio-pulmonary bypass, the automated activated clotting time (Hemochron ACT) became the routine method of monitoring heparinization in most ...
H. Kiefer +3 more
openaire +2 more sources
Current Opinion in Anaesthesiology, 2009
The nonspecific protease inhibitor aprotinin has been used successfully to reduce bleeding in cardiac surgery. Recent investigations have questioned its safety, and aprotinin has finally been withdrawn from marketing after a large prospective study demonstrated a trend toward higher mortality.The initial studies of Karkouti and Mangano provoked a ...
openaire +3 more sources
The nonspecific protease inhibitor aprotinin has been used successfully to reduce bleeding in cardiac surgery. Recent investigations have questioned its safety, and aprotinin has finally been withdrawn from marketing after a large prospective study demonstrated a trend toward higher mortality.The initial studies of Karkouti and Mangano provoked a ...
openaire +3 more sources
Plant Biotechnology Journal, 2010
Plants have been proposed as an attractive alternative for pharmaceutical protein production to current mammalian or microbial cell-based systems. Eukaryotic protein processing coupled with reduced production costs and low risk for mammalian pathogen ...
G. Pogue +17 more
semanticscholar +1 more source
Plants have been proposed as an attractive alternative for pharmaceutical protein production to current mammalian or microbial cell-based systems. Eukaryotic protein processing coupled with reduced production costs and low risk for mammalian pathogen ...
G. Pogue +17 more
semanticscholar +1 more source
Aprotinin—Are There Lessons Learned?
JAMA, 2007THIS PAST YEAR HAS BEEN A COMPLICATED ONE FOR aprotinin, an antifibrinolytic serine protease inhibitor used to lessen bleeding in patients undergoing cardiac surgery with cardiopulmonary bypass. Thirteen years after the initial approval of aprotinin by the US Food and Drug Administration, the report by Mangano and colleagues in this issue of JAMA will ...
openaire +2 more sources